Dataset from Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' HPV-16/18 L1 AS04 Vaccine When Administered According to Alternative 2-dose Schedules in 9 - 14 Year Old Females

This study has been designed to evaluate the immunogenicity and safety of GSK Biologicals' HPV-16/18 vaccine when administered according to alternative 2-dose schedules (0,6 months and 0,12 months) in healthy 9-14 year old females as compared to the standard 3-dose schedule (0,1,6 months) in 15-25 year old females.

本研究旨在评估葛兰素史克生物制品（GSK Biologicals）的人乳头瘤病毒16/18型（HPV-16/18）疫苗，以两种替代2剂接种方案（0、6个月及0、12个月程序）接种于健康9-14岁女性时的免疫原性与安全性，并与15-25岁健康女性采用标准3剂接种方案（0、1、6个月程序）接种的情况进行对比。